Uncategorized
VIDEO: Comparison of large trials shows similar results with anti-VEGFs for CRVO, BRVO
NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Theodore Leng, MD, discusses a poster presentation reviewing the treatment of branch retinal vein occlusion and central retinal vein occlusion among the three anti-VEGF agents at 6 months. The study showed similar treatment outcomes for bevacizumab, ranibizumab and aflibercept.